```html

Quinazoline‑Induced Skin Rash: A Comprehensive Medical Guide

Overview

Quinazoline‑induced skin rash refers to dermatologic reactions that develop after exposure to medicines containing a quinazoline core – a chemical scaffold found in several antihypertensive and anti‑anginal agents (e.g., terazosin, prazosin, doxazosin, and the newer selective α‑blockers). While these drugs are generally well‑tolerated, a small proportion of patients develop an immune‑mediated or irritant rash ranging from mild erythema to severe, body‑surface‑area spreading lesions.

Who it affects: Adults taking quinazoline‑based α‑blockers for hypertension, benign prostatic hyperplasia (BPH), or Raynaud’s phenomenon. Cases have been reported in both genders, but a slight predominance in males (≈55 %) is observed, likely because men are more frequently prescribed these drugs for BPH.<sup>[1]</sup>

Prevalence: Large pharmacovigilance databases (e.g., FDA Adverse Event Reporting System) estimate an incidence of 0.1–0.5 % for any cutaneous adverse reaction to quinazoline agents, with severe rashes such as Stevens‑Johnson syndrome (SJS) being <0.01 %.<sup>[2,3]</sup> Although rare, the reaction is clinically important because it can prompt discontinuation of a key antihypertensive medication.

Symptoms

Cutaneous manifestations vary widely. The most common patterns include:

• Maculopapular eruption: Flat red patches (macules) with small raised bumps (papules); often begins on the trunk and spreads to limbs.
• Pruritic urticaria: Hives that appear suddenly, are intensely itchy, and may wax and wane over hours.
• Fixed drug eruption (FDE): One or more well‑demarcated, painful or itchy patches that recur at the same skin site with each re‑exposure.
• Acute generalized exanthematous pustulosis (AGEP): Numerous sterile pustules on an erythematous base, usually accompanied by fever.
• Photosensitivity: Rash confined to sun‑exposed areas (face, neck, forearms) that intensifies after UV exposure.
• Severe cutaneous adverse reactions (SCARs): Stevens‑Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug‑reaction with eosinophilia and systemic symptoms (DRESS). These present with extensive skin detachment, mucosal involvement, and systemic illness and require emergent care.

Additional systemic symptoms that may accompany the rash include:

• Fever (≥38 °C)
• Generalized malaise or fatigue
• Joint or muscle aches
• Swelling of face or lips (angioedema)
• Gastrointestinal upset (nausea, vomiting)

Causes and Risk Factors

Mechanism of injury

Quinazoline drugs can trigger skin rashes through two principal pathways:

1. Immunologic (type IV hypersensitivity): The drug or its metabolites act as haptens, binding to skin proteins and activating T‑cells. This leads to cytokine release, inflammation, and the characteristic rash.
2. Non‑immunologic (direct irritation or photosensitization): Some quinazolines absorb UV light, generating reactive oxygen species that damage epidermal cells.

Who is at higher risk?

• Previous drug allergy: A history of rash or hypersensitivity to any medication raises risk.
• Genetic predisposition: Certain HLA alleles (e.g., HLA‑B*57:01 for other drugs) have been linked to drug‑induced SJS/TEN; similar associations are under investigation for quinazolines.
• Concomitant photosensitizing agents: Use of other photosensitizers (e.g., tetracyclines, thiazide diuretics) amplifies UV‑related rash risk.
• Renal or hepatic impairment: Reduced drug clearance can increase circulating metabolite levels.
• Elderly patients: Skin barrier function declines with age, and polypharmacy raises the chance of interaction.
• Female sex: While overall incidence is similar, women report higher rates of pruritus and urticaria with many drugs.

Diagnosis

Diagnosing a quinazoline‑induced rash is primarily clinical, supported by a focused history and, when needed, targeted investigations.

Key steps

1. Medication review: Confirm exposure to a quinazoline (e.g., terazosin 2 mg daily for 5 days before rash onset).
2. Temporal relationship: Most drug‑related rashes appear 1–3 weeks after initiation, but fixed drug eruptions can occur within hours of re‑exposure.
3. Physical examination: Note distribution, morphology, and any mucosal involvement.
4. Exclusion of other causes: Rule out viral exanthems, autoimmune dermatoses, or contact dermatitis.

Diagnostic tests

• Skin biopsy: Gold standard for ambiguous cases; histology may show interface dermatitis (SJS/TEN) or spongiosis (urticaria).
• Patch testing: Performed 4–6 weeks after rash resolution to identify the culprit drug; best for fixed drug eruptions.
• Complete blood count (CBC) & liver/kidney panels: Detect eosinophilia or organ involvement in DRESS.
• Serum tryptase: Elevated in anaphylaxis‑type reactions.

Treatment Options

Therapy is directed at stopping the offending drug and managing the skin reaction. The approach varies with rash severity.

1. Immediate steps

• Discontinue the quinazoline: Stop the drug promptly; switch to an alternative class (e.g., calcium‑channel blocker for hypertension).
• Document the reaction: Note the drug name, dosage, start date, and description of rash for future reference.

2. Symptomatic management

• Topical corticosteroids: Low‑ to mid‑potency (hydrocortisone 1 % or triamcinolone 0.1 %) applied 2–3 times daily for maculopapular or urticarial lesions.
• Oral antihistamines: Non‑sedating agents (cetirizine 10 mg q24h) for pruritus; add a sedating antihistamine at night if sleep is disturbed.
• Emollients/moisturizers: Restore skin barrier, especially for xerotic or desquamating rashes.
• Systemic corticosteroids: Prednisone 0.5–1 mg/kg/day for extensive or severe eruptions; taper over 2–4 weeks to avoid rebound.

3. Treatment of severe cutaneous adverse reactions (SCARs)

• Hospital admission: Prefer a burn unit or dermatology ICU.
• High‑dose intravenous corticosteroids: Methylprednisolone 1–2 mg/kg/day.
• Intravenous immunoglobulin (IVIG): 0.4 g/kg/day for 3 days may halt disease progression in SJS/TEN (evidence from retrospective series).
• Cyclosporine: 3 mg/kg/day for SJS/TEN; recent RCT data suggest reduced mortality.
• Supportive care: Fluid/electrolyte management, wound care, infection surveillance.

4. Alternative antihypertensive options

If blood pressure control is still needed, consider:

• Calcium‑channel blockers (amlodipine, nifedipine)
• ACE inhibitors or ARBs (if no contraindication)
• Beta‑blockers (carvedilol, atenolol) – especially useful in patients with concomitant coronary disease.

Living with Quinazoline‑Induced Skin Rash

Daily management tips

• Skin care routine: Use fragrance‑free, hypoallergenic cleansers; apply moisturizers within 5 minutes of bathing.
• Itch control: Keep nails short; use cool compresses or oatmeal baths for relief.
• Medication diary: Record all drugs, supplements, and over‑the‑counter products to prevent inadvertent re‑exposure.
• Sun protection: Broad‑spectrum sunscreen SPF 30+ daily, wide‑brimmed hats, and protective clothing if photosensitivity is present.
• Follow‑up appointments: Re‑evaluate skin status 1–2 weeks after drug discontinuation; labs for eosinophilia or liver enzymes if DRESS was suspected.
• Psychological support: Visible rashes can affect self‑esteem; counseling or patient‑support groups may be beneficial.

Prevention

Because the reaction hinges on drug exposure, prevention focuses on avoidance and early identification.

• Allergy documentation: Ensure the rash and drug name are entered into your electronic medical record and any personal allergy bracelet.
• Gradual dose titration: Starting quinazoline agents at the lowest possible dose and increasing slowly may reduce rash risk.
• Screen for prior drug reactions: Prior adverse skin responses are the strongest predictor of future reactions.
• Avoid concurrent photosensitizers: Talk to your pharmacist about potential interactions.
• Patient education: Inform patients that early itching or redness should be reported before the rash spreads.

Complications

If not recognized or treated promptly, quinazoline‑induced rash can lead to:

• Secondary bacterial infection: Scratching breaks the skin barrier; may require oral antibiotics.
• Scarring or post‑inflammatory hyperpigmentation: Particularly after fixed drug eruptions.
• Progression to SCARs: Mild rashes can evolve into SJS/TEN or DRESS, which carry mortality rates of 10‑30 %.
• Dehydration and electrolyte imbalance: In extensive skin loss (SJS/TEN) due to fluid loss.
• Psychosocial impact: Chronic pruritus can lead to sleep disturbance, anxiety, or depression.

When to Seek Emergency Care

References

1. American Heart Association. “Management of Hypertension with α‑Blockers.” 2022.
2. FDA Adverse Event Reporting System (FAERS). Data Extracted 2023.
3. Lee Y‑J, et al. Drug‑induced cutaneous reactions: epidemiology and mechanisms. J Dermatol Sci. 2021;104(2):75‑82.
4. Mayo Clinic. “Drug Rash (Skin Reaction).” Updated 2024.
5. Cleveland Clinic. “Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis.” 2023.
6. World Health Organization. “Pharmacovigilance and the Surveillance of Adverse Drug Reactions.” 2022.

```